Search for: [Abstract = "mended by expert bodies for the treatment of hand eczema \(HE\), 382 medicinal products with 41 active substances, and 21 emollients were licensed to the Polish market. Out of these, only 6 local GCS preparations with 2 active substances \(betamethasone, diflucortolone valerate\), one oral preparation of the retinoid alitretinoin \(9\-cis\-retinoic acid\), and one emollient had the official indication for the treatment of this condition. Only one medicinal product registered for treating hand eczema contained an active substance with effectiveness confirmed in high\- or moderate quality clinical studies \(oral alitretinoin, high quality evidence\). No medicinal products were placed on the reimbursement list with the indication \"hand eczema\". Among medicinal products available in Poland but not registered for the treatment of hand eczema, none contained active substances with effectiveness in HE treatment confirmed in high\- or moderate quality clinical trials. The present analysis has also demonstrated that for some of the diseases from the spectrum of eczema, neither expert guidelines, nor drugs licensed for the given indication were available. Conclusions\: There are considerable discrepancies between expert recommendations for pharmacotherapy of diseases from the spectrum of eczema, the scientific evidence for the effectiveness of recommended drugs, and the acceptable use of the drugs a"]
